RxDoctor Payments Data

Julia Hill

Family · Charlottesville, VANPI 1285278390

Payments from drug & device makers

$972in general payments, 2019–2025

Across 25 payments — averaging $38.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$195
  • AbbVie$173
  • Novo Nordisk$154
  • Teva Pharmaceuticals USA, Inc.$102
  • Neurocrine Biosciences, Inc.$94
  • Amgen$74
  • plus $181 from 6 others

What the payments were for

  • Food & beverage$972100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$972 in reported general payments places this provider in the 70th percentile of 4,332 family providers in Virginia.

See all family providers in Virginia

Medicare billing

Part B allowed, 2024
$79
Medicare patients
15
Services billed
17

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide64$67,673
JardianceEmpagliflozin52$44,493
EliquisApixaban34$23,571
TrulicityDulaglutide20$22,568
MounjaroTirzepatide18$18,732
JanuviaSitagliptin Phosphate20$15,477
FarxigaDapagliflozin Propanediol15$14,036
Breo ElliptaFluticasone/Vilanterol21$8,550
VascepaIcosapent Ethyl19$6,659
Midodrine Hcl17$5,407
ShingrixVaricella-Zoster Ge/As01b/Pf24$4,990
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate24$4,158
Rosuvastatin Calcium259$3,286
Pregabalin55$2,526
Fluticasone Propionate HfaFluticasone Propionate12$2,516

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$154$67,67364 claims
Lilly USA, LLCTrulicity, Mounjaro$17$41,30038 claims
PfizerEliquis$68$23,57134 claims
MerckJanuvia$25$15,47720 claims
GSKBreo Ellipta, Shingrix$16$13,54145 claims
AbbVieSynthroid$173$1,21212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 4,332 family providers in Virginia.

Other family in Charlottesville

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →